Inclusion Criteria:

- Histologically confirmed squamous cell carcinoma of head and neck

- Age ≥ 18

- ECOG PS 0-2

- Documented progressive disease after platinum-based systemic chemotherapy (either
cisplatin or carboplatin) with or without cetuximab

- At least one bidimensionally measurable disease

- Adequate organ function for treatment

- Availability of tumor tissue for molecular analysis (archival or rebiopsy tissue)

Exclusion Criteria:

- Nasopharyngeal carcinoma

- Eligibility for local therapy (surgery or radiotherapy)

- Previous treatment with small molecule EGFR tyrosine kinase inhibitors

- More than one systemic chemotherapy

- Any major operation or irradiation within 4 weeks of baseline disease assessment

- Any clinically significant gastrointestinal abnormalities which may impair intake or
absorption of the study drug

- CNS metastasis with continuous corticosteroid use within 4 weeks of baseline disease
assessment

- Patients with known interstitial lung disease

- Patients with uncontrolled or significant cardiovascular disease (AMI within 12
months, Unstable angina within 6 months, NYHA Class III, IV Congestive heart failure
or left ventricular ejection fraction below local institutional lower limit of normal
or below 45%, Congenital long QT syndrome, Any significant ventricular arrhythmia,
Any uncontrolled second or third degree heart block, Uncontrolled hypertension)

- Concomitant malignancy (except adequately treated basal cell cancer of skin or
cervical cancer in situ)

- Pregnant or breast-feeding women

- Other severe acute or chronic medical condition or laboratory abnormality that may
increase the risk associated with trial participation or investigational product
administration or may interfere with the interpretation of trial results and, in the
judgment of the investigator, would make the patient inappropriate for entry into
this trial.